Search

Your search keyword '"Tajiri, Nobuhisa"' showing total 7 results
Start Over Author "Tajiri, Nobuhisa" Search Limiters Full Text
7 results on '"Tajiri, Nobuhisa"'

2. An Adult Case of Nasal Chondromesenchymal Hamartoma: Imaging Characteristics Including Diffusion-Weighted Images

Author

Kitayama, Takahiro, Akaki, Shiro, Hisazumi, Kento, Yoshio, Kotaro, Inoue, Daisaku, Tajiri, Nobuhisa, Shiode, Tsuyoki, Kanazawa, Susumu, Fujimoto, Shohei, Kanai, Kengo, and Hirata, Yuji

Subjects
Male, Young Adult, nasal chondromesenchymal hamartoma, diffusion-weighted imaging, Hamartoma, Nose Neoplasms, magnetic resonance imaging, Humans, computed tomography
Abstract

Nasal chondromesenchymal hamartoma (NCMH), a rare, benign, nasal cavity tumor, typically occurs in children. Differential diagnosis is difficult because NCMH often presents with non-specific findings, including cystic components and invasion of the surrounding area on T2-weighted magnetic resonance images. Here, we present a rare adult case of NCMH, with no clear hyperintensity on diffusion-weighted images (DWI), and bone remodeling on the tumor margins on computed tomography. To the best of our knowledge, this is the first report of DWI on NCMH, and these findings, which suggest benign disease, may be useful in diagnosing NCMH.

Published
2019

3. Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Middle or Lower Esophageal Cancer Using Elective Nodal Irradiation: Comparison with 3D Conformal Radiotherapy

Author

Yoshio, Kotaro, Wakita, Akihisa, Mitsuhashi, Toshiharu, Kitayama, Takahiro, Hisazumi, Kento, Inoue, Daisaku, Tajiri, Nobuhisa, Shiode, Tsuyoki, Akaki, Shiro, and Kanazawa, Susumu

Subjects
volumetric modulated arc therapy, 3D-CRT, Aged, 80 and over, Male, Esophageal Neoplasms, elective nodal irradiation, Middle Aged, Radiation Dosage, middle and lower thoracic, Humans, Female, esophageal cancer, Lymph Nodes, Radiotherapy, Intensity-Modulated, Radiotherapy, Conformal, Lung, Aged
Abstract

We investigated the feasibility of simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) using elective nodal irradiation (ENI) for middle or lower esophageal cancer and compared it with three-dimensional conformal radiotherapy (3D-CRT). The study included 15 patients. The prescribed doses included a standard dose (50.4 Gy) and a high dose (60 Gy) for the planning target volume (PTV) of the involved lesions. The objective of the whole lung volume receiving ≥ 20 Gy (V20Gy) was < 30%, and the mean lung dose (MLD) was < 20 Gy. The volumes of the lung receiving 5 Gy (V5Gy) and the heart receiving 30-50 Gy (V30-50Gy) were kept as low as reasonably achievable. As a result, SIB-VMAT showed superior dose conformity for the PTV (p 20% reduction in the mean against 3D-CRTs. Our results demonstrate the feasibility of SIB-VMAT for the treatment of middle or lower esophageal cancer with ENI. Although attention should be paid to the low-dose area of the lungs, SIB-VMAT would be a promising treatment option with improved outcomes for esophageal cancer.

Published
2019

4. Radiofrequency ablation followed by radiation therapy for large primary lung tumors

Author

Mukai, Takashi, Mimura, Hidefumi, Gobara, Hideo, Takemoto, Mitsuhiro, Himei, Kengo, Hiraki, Takao, Hase, Soichiro, Fujiwara, Hiroyasu, Iguchi, Toshihiro, Tajiri, Nobuhisa, Sakurai, Jun, Yasui, Kotaro, Sano, Yoshifumi, Date, Hiroshi, and Kanazawa, Susumu

Subjects
Aged, 80 and over, Male, Reoperation, Lung Neoplasms, Time Factors, respiratory system, Middle Aged, radiation therapy, Combined Modality Therapy, Radiography, lung cancer, Treatment Outcome, Carcinoma, Non-Small-Cell Lung, Catheter Ablation, Humans, radiofrequency ablation, Follow-Up Studies
Abstract

We report the clinical experience of radiofrequency ablation followed by radiation therapy for large primary lung tumors. Two patients with large primary lung tumors were treated with combined radiofrequency ablation and radiation therapy, and good local control was observed. Combined radiofrequency ablation and radiation therapy that involves minimally invasive techniques appears to be promising for the treatment of large lung tumors.

Published
2007

6. Local Control of Squamous Cell Carcinoma of the Cervix Treated with CT-based Three-dimensional Image-Guided Brachytherapy with or without Central Shielding.

Author

Yoshio K, Nagasaka H, Hisazumi K, Okawa H, Tajiri N, Shiode T, Akaki S, Kanazawa S, Mitoma T, Yano Y, Kobayashi E, Horiguchi I, Takata M, Hongo A, Yonezawa M, and Nakanishi Y

Subjects
Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Female, Humans, Imaging, Three-Dimensional, Middle Aged, Radiotherapy Dosage, Retrospective Studies, Tomography, X-Ray Computed, Uterine Cervical Neoplasms pathology, Brachytherapy methods, Carcinoma, Squamous Cell radiotherapy, Radiotherapy, Conformal methods, Uterine Cervical Neoplasms radiotherapy
Abstract

The purposes of this retrospective study were to analyze local control of squamous cell carcinoma of the cervix treated with computed tomography (CT)-based image-guided brachytherapy (IGBT), as well as the factors affecting local control. A total of 39 patients were analyzed. The prescribed dose to the pelvis was 45-50 Gy with or without central shielding (CS). IGBT was delivered in 1-5 fractions. The total dose for high-risk clinical target volume (HR-CTV) was calculated as the biologically equivalent dose in 2-Gy fractions. The median follow-up period was 29.3 months. The 2-year overall survival and local control rates were 97% and 91%, respectively. In univariate analysis, the dose covering 90% of the HR-CTV (D90) and tumor size were found to be significant factors for local control. The cutoff values of tumor size and D90 for local control were 4.3 cm (area under the curve [AUC] 0.75) and 67.7 Gy (AUC 0.84) in the CS group and 5.3 cm (AUC 0.75) and 73.7 Gy (AUC 0.78) in the group without CS, respectively. However, though the local control of CT-based IGBT was favorable, the results suggested that the dose required for tumor control may differ depending on the presence of CS., Competing Interests: No potential conflict of interest relevant to this article was reported.

Published
2021
Full Text
View/download PDF

7. Radiofrequency ablation of lung cancer at Okayama University Hospital: a review of 10 years of experience.

Author

Hiraki T, Gobara H, Mimura H, Toyooka S, Fujiwara H, Yasui K, Sano Y, Iguchi T, Sakurai J, Tajiri N, Mukai T, Matsui Y, and Kanazawa S

Subjects
Algorithms, Disease Progression, Humans, Lung Neoplasms pathology, Survival Rate, Tomography, X-Ray Computed, Catheter Ablation adverse effects, Catheter Ablation methods, Lung Neoplasms surgery
Abstract

The application of radiofrequency ablation for the treatment of lung cancer by our group at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences began in June 2001, and in the present report, we review our 10-year experience with this treatment modality at Okayama University Hospital. The local efficacy of radiofrequency ablation for the treatment of lung cancer depends on tumor size and the type of electrode used, but not on tumor type. An important factor for the prevention of local failure may be the acquisition of an adequate ablative margin. The combination of embolization and radiation therapy enhances the local efficacy. Local failure may be salvaged by repeating the radiofrequency ablation, particularly in small tumors. Survival rates after radiofrequency ablation are quite promising for patients with clinical stage I non-small cell lung cancer and pulmonary metastasis from colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma. The complications caused by radiofrequency ablation can be treated conservatively in the majority of cases. However, attention should be paid to rare but serious complications. This review shows that radiofrequency ablation is a promising treatment for patients with lung cancer.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results